Analystreport

Progenics Pharmaceuticals (NASDAQ: PGNX) was given a new $15.00 price target on by analysts at Cantor Fitzgerald. They now have a "buy" rating on the stock.

PROGENICS PHARMACEUTICALS  (PGNX) 
Last progenics pharmaceuticals earnings: 8/9 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: progenics.com